Categories: News

Athira Pharma to Present at Upcoming Investor Conferences

–   JMP Securities Life Sciences Conference

–   Raymond James Human Health Innovation Conference

BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira“), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that company management will participate in the following upcoming investor conferences:

  JMP Securities Life Sciences Conference
    Format: Fireside chat
    Date: Thursday, June 17, 2021
    Time: 3:30 PM ET
     
  Raymond James Human Health Innovation Conference
    Panel Topic: Neurodegenerative Diseases: New & Improved Therapeutic Targets for Alzheimer’s & Parkinson’s Disease
    Participant: Mark Litton, Ph.D., MBA, Chief Operating Officer
    Date: Monday, June 21, 2021
    Time: 1:20 PM ET

A live webcast of each presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for at least 30 days following the event.

For more detail and to register for the events above, please visit https://investors.athira.com/news-and-events/events-and-presentations

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on FacebookLinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Julie.rathbun@athira.com
206-769-9219

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

13 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

16 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

16 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

16 hours ago